Processa Pharmaceuticals Announces Pricing of $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules
January 27, 2025 20:30 ET
|
Processa Pharmaceuticals, Inc.
HANOVER, MD, Jan. 27, 2025 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next...
Fortress Biotech Announces Pricing of $8 Million Registered Direct Offering and Concurrent Private Placements
September 20, 2024 08:30 ET
|
Fortress Biotech, Inc.
MIAMI, Sept. 20, 2024 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress” or “Company”), an innovative biopharmaceutical company focused on acquiring and advancing assets to...
Fortress Biotech to Participate in the Alliance Global Partners’ (A.G.P.) Virtual Healthcare Company Showcase
May 16, 2024 08:00 ET
|
Fortress Biotech, Inc.
MIAMI, May 16, 2024 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term...
Journey Medical Corporation to Participate in the Alliance Global Partners’ (A.G.P.) Virtual Healthcare Company Showcase
May 15, 2024 16:01 ET
|
Journey Medical Corporation
SCOTTSDALE, Ariz., May 15, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or “the Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company that primarily focuses...
GRI Bio Announces Pricing of $5.5 Million Public Offering
February 02, 2024 08:00 ET
|
GRI Bio, Inc.
LA JOLLA, CA, Feb. 02, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell...
Bukit Jalil Global Acquisition 1 Ltd. Announces the Separate Trading of its Ordinary Shares, Warrants, and Rights, Commencing on August 21, 2023
August 17, 2023 08:00 ET
|
Bukit Jalil Global Acquisition 1 Ltd.
New York, NY, Aug. 17, 2023 (GLOBE NEWSWIRE) -- Bukit Jalil Global Acquisition 1 Ltd. (the “Company”) (Nasdaq: BUJA), a blank check company, today announced that, commencing on August 21, 2023,...
CELSION CORPORATION ANNOUNCES $7.0 MILLION REGISTERED DIRECT OFFERING PRICED AT-THE-MARKET UNDER NASDAQ RULES
April 06, 2022 08:30 ET
|
Celsion Corporation
LAWRENCEVILLE, NJ, April 06, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) (“Celsion” or the “Company”), today announced it has entered into definitive agreements with institutional...
Celsion Corporation Announces Pricing of $30 Million Registered Direct Offerings of Convertible Redeemable Preferred Stock
January 10, 2022 20:45 ET
|
Celsion CORP
LAWRENCEVILLE, N.J., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines, today...
Qualigen Therapeutics, Inc. Announces Closing of $8.82 Million Registered Direct Offering
December 01, 2021 15:25 ET
|
Qualigen Therapeutics, Inc.
CARLSBAD, Calif., Dec. 01, 2021 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN) today announced the closing of its previously announced registered direct offering with certain...
MICHAEL SHILLIN INVESTOR ALERT: National Investor Fraud Law Firm KlaymanToskes Commences Investigation of Financial Advisor Michael Shillin in Light of SEC lawsuit and FINRA bar
October 28, 2021 16:53 ET
|
Klayman & Toskes P.A.
WISCONSIN, Oct. 28, 2021 (GLOBE NEWSWIRE) -- National investor fraud law firm, KlaymanToskes (“KT”), has commenced an investigation of potential FINRA arbitration claims of financial advisor Michael...